# Damora Therapeutics Inc. (DMRA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $30.06, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Damora Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.8×**. The shares trade at 4.8× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -87.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 121.5%**. Earnings per share rose 121.5%.

## Financial health
- **Current ratio: 12.98** (quick 12.98). Current assets cover the next year's liabilities 12.98 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Damora Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Damora Therapeutics Inc.; the consensus is strong_buy, with an average price target of $44.67 (+49% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 902.0%** (YTD 30.6%, 3-mo 43.1%). The shares are up 902.0% over twelve months including dividends.
- **From 52-week high: -21.6%** (1126.9% above the low). Trading 22% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 1.96** (volatility 474%). Beta of 1.96 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DMRA · Page: https://foliofundamentals.com/stocks/dmra

Not investment advice.